ADAP Advocacy has published a retrospective white paper examining the 340B Drug Pricing Program, arguing that reform is necessary to realign the program with its original legislative intent of helping low-income patients access affordable care. The paper, titled "340B Program: The Glue That Should Hold Our Healthcare System Together," highlights how the program's growth has outpaced transparency and accountability, leading to concerns that provider interests now overshadow patient needs.
The 340B Program is the second-largest federal prescription drug program in the United States, behind Medicare Part D. According to the white paper, the program has veered from its original purpose, prioritizing provider profits over patient access to care. Brandon M. Macsata, CEO of ADAP Advocacy, emphasized the need for greater transparency across the healthcare system, including the 340B Program. "There is an ongoing effort to push for greater transparency across multiple layers of this country's fragmented healthcare system, including hospitals' patient billing practices and pharmacy benefit managers' spread pricing policies. The 340B Program shouldn't be excluded from this broader effort, especially since the ultimate goal is improved program efficiency, leading to greater access to care and treatment for low-income patients," Macsata stated.
The white paper raises three central questions: If 340B is designed to expand access and reduce financial burden, why are patients increasingly unable to afford care? Why is 340B not adequately addressing this problem? And why is it failing to meet the needs of the uninsured and underinsured, the very persons it was designed to serve? The paper argues that a program of this size and importance cannot rely on good faith alone; instead, improved accountability and transparency guardrails are needed to ensure its success for intended beneficiaries: patients.
The full white paper is available online at ADAP Advocacy's website. ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs and improve access to care for persons living with HIV/AIDS. The organization works with advocates, community, health care, government, patients, and pharmaceutical companies to raise awareness and foster greater community collaboration.
